Here is a puzzle from our own data. When we asked people how much FDA approval would matter in deciding whether to try a new depression treatment, a clear majority said a great deal. Yet when they had to name only two provider traits worth caring about, FDA approval sank toward the bottom.

Both answers are real. Together they say something useful about how people in the Midwest actually weigh a medical decision.

The survey

We paid for a poll of 443 adults, 18 to 64, spread over ten Midwest states from Ohio to Oklahoma. It closed in late June 2026 after running on a consumer panel. The questions focused on ketamine and esketamine therapy for depression and PTSD, and on what would shape a decision to try them. Its numbers are the final, validated set.

Finding one: FDA approval carries weight

On the question of how heavily FDA approval would count in trying the treatment, the answers split this way:

Combine the first two lines and 59 percent of respondents gave FDA approval heavy weight. Only about one in seven said it would not matter at all. On its own terms, the regulatory stamp is a serious consideration for most people.

Finding two: when forced to choose, other things win

A second question had respondents choose just two priorities for picking where to get this treatment. The ranking flipped:

FDA approval finished just ahead of fast results, well behind coverage and proximity. Roughly a quarter put it in their top two.

Reading the two findings together

We think the most sensible interpretation is that FDA approval works like a floor, not a feature. People want it. Most would think twice about a treatment without it. But once a treatment clears that bar, it stops being the thing they compare providers on. The comparison shifts to practical questions: will my plan pay for it, and can I get there?

That reading fits another result. Rated by itself, insurance landed a little above FDA approval, with 65 percent of respondents calling coverage deciding or big. The difference is that when the two compete directly, coverage wins by a landslide.

We should be cautious. This is one survey, the figures cover the whole sample, and stated priorities do not always predict behavior. But the pattern is consistent enough to take seriously.

Why this matters for depression treatment specifically

In depression care, the gap between approved and not approved is unusually relevant, because the ketamine landscape mixes both.

Spravato, the esketamine brand, won FDA approval for stubborn depression that standard care failed to lift, and patients take the spray in a certified clinic with staff present. Plain ketamine carries approval as an anesthetic; infusing it for depression is off-label. Ketamine sent home through a telehealth prescription, sometimes compounded, is further still from anything the FDA reviewed. Brain Recovery Centers lays out what the approved Spravato route involves for anyone sorting these apart.

For the 59 percent who say approval weighs heavily, those distinctions are not trivia. They are the difference between a treatment that meets their standard and one that may not.

The awareness problem

Here is the difficulty. People care about FDA approval, but they mostly do not know which treatments have it. The approved product, Spravato, was unknown to 73 percent of our respondents. A further 21 percent knew the name and nothing more, so only 6 percent could explain what it is.

That creates a strange situation. A person who cares about approval and hears the word "ketamine" in a news story has no easy way to tell which version is being discussed. The approved option and the unregulated one sound the same from the outside.

How people said they would find out

Respondents were clear about whom they would ask. Their own doctor was the voice most likely to get them to try it, the pick of 74 percent. Ads managed 2 percent.

As a first stop, primary care drew 56 percent of respondents and a psychiatrist 23 percent. Searching online on their own was far behind at 12 percent. And when 319 respondents typed out the words they would search, they wrote "help with depression" or "depression medicine alternatives," never a treatment name or its regulatory status.

So the person most people trust to sort approved from unapproved is their doctor. That is probably the right instinct.

Practical takeaways for weighing a treatment

None of these questions should come ahead of your safety. When suicidal thoughts press in, put the FDA questions down and contact 988. A Suicide and Crisis Lifeline counselor picks up a call or a text nationwide, at any hour.

Methodology

Respondents came from the Pollfish consumer panel, and fieldwork ended on June 23, 2026. We count 443 completed questionnaires from people 18 to 64 in Iowa, Wisconsin, Kansas, Illinois, Oklahoma, Minnesota, Ohio, Indiana, Nebraska and Missouri, every one past a consent screener. Items with multiple picks sum past 100 because each option is a share of all respondents. Pollfish has since validated the results, so they are final. Our publisher both commissioned and financed the research.